Genmab’s Petosemtamab Combination Cuts Death Risk 50% in Phase 3 Head and Neck Cancer Trial

Bitget2026/10/28 13:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab reported positive Phase 3 LiGeR-HN1 results for petosemtamab with pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck cancer.
The combination significantly improved overall survival and tumor response versus pembrolizumab alone at the first interim analysis, meeting both primary endpoints.
Benefits were observed regardless of HPV status; no new safety signals emerged.
Global regulatory discussions are planned, with full trial results to be submitted for presentation at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20261028593187) on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab’s Petosemtamab Combination Cuts Death Risk 50% in Phase 3 Head and Neck Cancer Trial

You may also like

Crypto prices